Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium and ECT in Depression
NCT05923476Phase 1Unknown
- Sponsor
- Melbourne Health
- Start
- Jun 2023
- Primary completion
- May 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing Lithium + ECT with Placebo + ECT (2 arms). Primary endpoint: Feasibility and safety of conducting a randomized controlled trial at 2 years. Status: unknown.
02
Drugs
lithium
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05923476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05923476.